Human herpesvirus 6 in the pathogenesis of multiple sclerosis

Review article

MALIN ENBOM

Department of Virology, Swedish Institute for Infectious Disease Control, Solna, Sweden

Enbom M. Human herpesvirus 6 in the pathogenesis of multiple sclerosis. APMIS 2001;109:401–11.

Multiple sclerosis (MS) is one of the most common disabling neurological diseases affecting young adults. It is a chronic disease characterised by inflammation and demyelination. The aetiology of MS is still unknown, but involvement of viruses has been suspected for many years. Recently much interest has focused on human herpesvirus 6 (HHV-6), since the virus has been detected in MS plaques in the brain and patients with MS have been shown to have an aberrant immune response to HHV-6. Results from different studies are, however, conflicting and in the light of the long list of previous claims to have found the viral aetiology of MS it is necessary to interpret the HHV-6 findings with great caution. Possible mechanisms for virally induced demyelination and autoimmunity are discussed in this review, and the evidence for and against a role for HHV-6 in MS is summarised.

Key words: Multiple sclerosis; pathogenesis; human herpesvirus 6.

Malin Enbom, Department of Virology, Swedish Institute for Infectious Disease Control, S-171 82 Solna, Sweden. e-mail: malin_enbom@hotmail.com

MULTIPLE SCLEROSIS

The clinical picture of multiple sclerosis (MS) is extremely variable, reflecting the widespread affection of the central nervous system (CNS). The most common symptoms include impaired vision (caused by optic neuritis), sensory symptoms, motor symptoms, spasticity, ataxia, fatigue, incontinence, and cognitive impairment. The disease is usually divided into two types, relapsing-remitting MS and primary progressive MS. In most patients (85%), MS begins as relapsing-remitting MS with episodes of neurological symptoms followed by substantial or complete improvement. With time and repeated relapses, recovery is often less complete and a gradual relapse-independent clinical progression develops called secondary progressive MS. The age of onset of disease for relapsing-remitting MS is usually between 20 and 40 years. In primary progressive MS the decline in neurological function is gradual. This form of MS occurs particularly in patients in whom symptoms develop after the age of 40 years and primary progressive MS also has a slight male predominance while relapsing-remitting MS has a female:male ratio of 2:1.

PATHOLOGY

MS lesions are multifocal, and the distribution of lesions varies among different patients. However, there is a predilection for involvement of the optic nerve, periventricular white matter, brain stem and spinal cord (1). The reason for this is not completely understood, but might relate to a distinct microenvironment in these sites. For example, the proximity to the flow of cerebrospinal fluid and rich vascular perfusion might result in high concentrations of circulating inflammatory mediators, of other plasma proteins, or of blood-borne infectious agents. Alternatively, there is an as yet unknown differ-

401

ence in composition of myelin r extracellular matrix in these areas. Macroscopically, the MS plaques are well circumscribed and grossly visible and do not reflect any specific anatomic tract. The histological features of a typical MS lesion are infiltration of immune cells into the CNS and destruction of oligodendrocytes resulting in plaques of demyelination. The axons are relatively preserved, but axonal loss occurs and might be responsible for irreversible neurological disability in MS (2). An early event in all CNS immune reactions, and also in MS, is the enhanced expression of adhesion molecules on endothelial cells mediating extravasation of leukocytes. As immune cells migrate into the CNS, perivascular leakage occurs followed by complete disruption of microvascular wall integrity which permits inflow of plasma proteins into the brain parenchyma (1). The inflammatory cells found in the plaques are predominantly lymphocytes (mainly T-cells but also B-cells) and macrophages. The macrophages are foamy (lipid-rich) since they actively phagocytose myelin (3). In the initial phase of MS, oligodendrocytes are preserved in the lesions, immature oligodendrocytes proliferate, and remyelination can occur. In chronic plaques, however, the number of oligodendrocytes is decreased and remyelination is impaired (1).

EPIDEMIOLOGY

There is an uneven geographical distribution of MS with a much higher frequency in temperate zones compared to around the equator. This could mean that the environment is of importance for MS pathogenesis, but it might also reflect the distribution of genetically susceptible individuals. Migration studies have indicated that an environmental factor introduced to the individual at an early age is of importance for disease susceptibility, since children but not adults immigrating from a high risk to a low risk area (but not vice versa) acquire the risk of the new region (4). Great caution must, however, be exercised when interpreting results from migrations studies, since the migrants may not be representative of the population in their country of origin. Reports of clustering or "epidemics" of MS cases have also been used to suggest an important environmental influence, e.g.

an infection. An example of this is the steep increase in MS incidence in the Faroe islands after World War I, where it has been argued that British soldiers stationed on the island introduced an "MS agent" to the population (5).

AETIOLOGY

The aetiology of MS is still unknown, but it is generally presumed to be an autoimmune disease. It is likely that MS is caused by an interaction between genetic and environmental factors.

Genetics. There is increasing evidence that genetic factors have an important role in determining MS susceptibility. Large population-based studies of twins have shown a concordance rate of about 30% for monozygotic pairs and 2–3% for like-sex dizygotic pairs (6–8). These figures argue for two things: first, there is a substantial genetic component (which is probably polygenic); second, environmental factors are also of importance since the concordance rate is not 100% for monozygotic twins. Half-sibs have been shown to have the same risk of developing MS whether they are raised together or apart (9). This has been used as an argument against the importance of environmental factors in MS pathogenesis, but it might also reflect the role of a ubiquitous factor, such as a widespread infectious agent.

Immunology. MS patients show several aberrant immunological parameters. One important laboratory finding supporting the MS diagnosis is the local production of immunoglobulins in the CNS. This is seen on isoelectric focusing as oligoclonal bands present in cerebrospinal fluid (CSF), but not in serum from the same patient. The antigen specificities of the intrathecally produced immunoglobulins have been shown to be very varied. MS patients also have an increased immunological reactivity have an increased immunological reactivity against several myelin antigens, including myelin basic protein (10), myelin-associated glycoprotein (11), and myelin oligodendrocyte glycoprotein (12, 13). There are furthermore signs of a defect in immunological suppression in MS patients, such as lower suppressor activity of CD8+ cells and decreased levels of different T-lymphocyte subsets (14–16).

Virology. Generations of researchers have considered whether a virus might cause MS,

and more than 20 different viruses have been suggested as the "MS agent" (Table 1). The speculation that there is a viral aetiology of MS is based on several observations:

- Epidemiological studies have indicated that an environmental factor, possibly an infection, encountered in childhood is of importance for disease susceptibility (5).
- A late encounter with common childhood infections such as measles, mumps, and rubella is more common in MS patients than in control subjects (17).
- Viral infections may trigger as many as 25% of MS exacerbations (18, 19).
- Intrathecal antibody production to several viruses is seen in MS patients.
- Other demyelinating diseases have definitely been shown to be caused by viruses, for example progressive multifocal leukoencephalopathy (JC-virus), postmeasles leukoencephomyelitis, and HIV encephalopathy.

There are several theories as to how a virus could cause demyelination. The most obvious and direct mechanism is, of course, a lytic virus infection resulting in destruction of oligodendrocytes. Alternatively, expression of viral antirocytes. Alternatively, expression of viral antigens on the surface of oligodendrocytes could lead to immune-mediated damage of the cells. Another concept is that of molecular mimicry,

i.e. antigenic similarity between the microbe and human tissue triggering the immune system to damage normal tissue. Several viruses show various degrees of sequence homology with components of the myelin sheet, but still the existence of this mechanism of disease remains to be proven. Finally, a virally encoded superantigen inducing activation and uncontrolled proliferation of B- and T-lymphocyte clones has been suggested as a possible inducer of immune-mediated injury. In contrast, there are various scenarios where the detection of a virus in MS plaques is an epiphenomenon and not causally linked to the disease. A virus infecting leukocytes might, for example, be passively carried into the inflammatory lesion in the CNS. A latent virus infection might also be reactivated by the increased levels of cytokines and other inflammatory mediators in the MS plaques. An additive role of this epiphenomenon in the pathogenesis can, however, not be ruled out.

MEASLES VIRUS

One of the most carefully studied viral agents in MS is measles virus. Acute measles causes immunosuppression, and one post-infectious complication is a demyelinating encephalomyelitis, raising the possibility that measles virus is involved in MS pathogenesis. The mechanism for measles virus-induced immunosuppression is not fully known. It has been shown, however, that measles virus infection downregulates IL-12, which is needed to generate cell-mediated immunity and drives the T-helper cell response towards T-helper 1 dominance (20). Since the original demonstration of higher antibody titres to measles virus in MS patients than in healthy controls (21), patients with MS have repeatedly been found to have elevated antibody titres to measles virus in both serum and CSF. Measles virus-like structures have also been seen by electron microscopy in MS brains (22). A late encounter with measles virus, but also other common infectious agents such as, for example, Epstein-Barr virus (EBV), has been correlated with an increased risk of developing MS (17). It has, however, not been possible to verify a role for measles virus in MS pathogenesis and the introduction of general vaccination pro-

TABLE 1. *Microorganisms suggested in MS pathogenesis*

Microorganism	Reference
Rabies	(88)
Measles virus	(21)
Herpes simplex virus	(87, 89)
Scrapie agent	(90)
Multiple sclerosis-associated agent	(91)
Parainfluenza virus 1	(92)
Simian virus 5	(93)
Chimpanzee cytomegalovirus	(94)
SMON-like virus	(95)
Tick-borne encephalitis	(96)
Human T-lymphotropic virus I	(97)
Paramyxovirus SV5	(98)
Multiple sclerosis-associated retrovirus	(24, 99)
Human herpesvirus 6	(62)
Canine distemper virus	(100)
Epstein-Barr virus	(101)
Varicella-zoster virus	(102)
Chlamydia pneumoniae	(103)

grammes against measles has so far not decreased the MS incidence.

RETROVIRUSES

Since human retroviruses are in general known to impair the immune system and since the human T-lymphotropic virus type I (HTLV-I) causes a chronic, inflammatory, demyelinating disease (23), extensive investigations to search for a human retrovirus in MS patients have been performed. In 1989 a new human retrovirus called MS-associated retrovirus (MSRV) was found, first in CSF and later in monocytes from MS patients but not from control subjects (24, 25). Recently other groups have reported on detection of retroviruses in blood from MS patients (26, 27). There is also the possibility of an interaction between different viruses, for example that a herpesvirus could trigger retroviral reactivation, as has been shown for HSV and MSRV, and suggested also for EBV (28, 29). Endogenous human retroviruses might come to provide new and interesting mechanisms for how autoimmune diseases are established, but such a link still remains to be proven.

HERPESVIRUSES

Another group of viruses that have been the focus of attention are the herpesvirus family. There are several features which make them attractive candidates: they are neurotropic, primary infection occurs early in life whereafter they remain latent and can be periodically reactivated, and they have the capacity to induce demyelination. HSV, varicella-zoster virus, and EBV have all been suggested to be involved in MS, but recently most interest has focused on human herpesvirus 6 (HHV-6).

HUMAN HERPESVIRUS 6

HHV-6 belongs to the Roseolovirus genus of the β-herpesvirus subfamily. HHV-6 infection occurs before the age of 3 in >90% of children, most frequently in the first year of life (30, 31). Horizontal spread through saliva is believed to be the most common route of

transmission (32). On the basis of DNA restriction analysis, in vitro cellular tropism, and reactivities of monoclonal antibodies, two distinct variants of HHV-6 (HHV-6A and HHV-6B) can be separated. HHV-6 variant B is the aetiological agent of exanthema subitum (roseola infantum) (33), whereas HHV-6 variant A has not definitely been linked to any human disease. The virus propagates primarily in CD4+ T-lymphocytes, but infection can occur in a variety of human cells such as macrophages, dendritic cells, astrocytes, oligodendrocytes, and neurons (34–37). The cellular receptor for HHV-6 has recently been identified as CD46, which is present on all nucleated human cells examined to date (38).

HHV-6 affects several mediators of the immune system. It has been shown to induce apoptosis of CD4+ T-cells (39, 40) and CD8+ cells and natural killer cells are also usually killed when infected. HHV-6 inhibits IL-2 production and T-cell proliferation (41, 42). It induces tumour necrosis factor-α, IL-1β, and IL-10 (41, 43), which have stimulatory effects on the immune system. The HHV-6 ORF U12 has been found to encode for a functional β-chemokine receptor (44). β-chemokines are chemotactic cytokines that attract monocytes, eosinophils, basophils, and lymphocytes, but have no effect on neutrophils (45).

NEUROLOGICAL COMPLICATIONS OF HHV-6 INFECTION

The neuroinvasive potential of HHV-6 has been demonstrated in both immunocompetent and immunosuppressed individuals. Furthermore, HHV-6 has been associated with a wide array of neurological symptoms in these patients. In children with exanthema subitum, HHV-6 DNA can be detected in the CSF in between 23 and 70% of cases, indicating that viral neuroinvasion frequently occurs in primary infection (46, 47). The most common neurological complication of primary HHV-6 infection is seizures (31) and HHV-6 accounts for 26–31% of febrile seizures in young children (31, 48). It has been suggested that HHV-6 variant A would have a greater neurotropism compared to variant B since HHV-6A is found relatively more frequently in CSF (14%) than in peripheral blood

mononuclear cells (PBMC) (1%) in children with primary HHV-6 infecti o (49).

HHV-6 can cause meningitis and encephalitis in children and adults, as described in several case reports (50–57). In one retrospective study, HHV-6 DNA was found in CSF from 9 (7%) of 138 patients with clinical or laboratory evidence of encephalitis (58). Another study found intrathecal production of IgG or IgM to HHV-6 early antigen but not to 26 other viruses in 10 (20%) of 50 patients with meningitis or encephalitis, whereas none of 50 controls had intrathecal antibodies to HHV-6 (59).

Demyelination has also been associated with HHV-6, since the virus has been found in plaques of demyelination in two immunosuppressed individuals (51, 54) as well as in two immunocompetent young women with lethal encephalitis (60, 61). One of these had been clinically and histopathologically diagnosed as having acute MS.

HHV-6 AND MULTIPLE SCLEROSIS

In 1995, Challoner et al. demonstrated the presence of the gene for an HHV-6 DNA-binding protein (p41) in MS brains (62). Immunohistochemical staining revealed the presence of the HHV-6 proteins p41 and 101K in the nuclei of oligodendrocytes in MS plaques, while controls were negative or (rarely) contained HHV-6 antigen in the cytoplasm of oligodendrocytes. This finding focused much interest on the possible pathogenic role of HHV-6 in MS and has led to several studies on this subject.

Patients with MS have been found to have higher antibody titres to HHV-6 in both serum and CSF as compared to control patients (63–65). IgM antibodies to HHV-6 have also been reported to be more prevalent in MS patients (63, 66, 67). PCR studies have found HHV-6 DNA in CSF at higher frequency among MS patients compared to controls (65, 68). However, several studies of humoral response (69–71) as well as of DNA detection in CSF (72–74) have not verified these findings. HHV-6 DNA has been detected in serum or cell-free plasma from MS patients but not from controls, suggesting a more active infection in MS patients. On the other hand, detection of only latent HHV-6 genomes in PBMC from MS patients

and rare detection of HHV-6 DNA in leukocytes from patients with relapsing-remitting MS argues against this (75, 76).

As mentioned previously, HHV-6 variant A has been suggested to be more neurotropic than variant B, since variant A was found to persist in CSF while variant B persisted in PBMC (49). Furthermore, the HHV-6A variant has been demonstrated in areas of demyelination in the CNS of AIDS patients (77). These findings point to the possibility of a role for the HHV-6A variant rather than the HHV-6B variant in MS, and there are reports supporting this. One study detected exclusively HHV-6A DNA sequences in PBMC from MS patients, while none of the controls had any detectable HHV-6 DNA in PBMC (78). Another study analysed the cellular immune response to HHV-6 in patients with MS, showing an increased lymphoproliferative response to HHV-6 variant A compared to controls (79).

In Table 2, data from several studies on HHV-6 and MS are summarised. As described above, the results from MS patients are conflicting. It is, however, important to note that there are large variations between the control groups used in different studies. For example, the frequency of detectable HHV-6 DNA in PBMC ranges from zero to 75%, and the frequency of HHV-6 IgM ranges from 2.5 to 18% between different control groups. This makes it very difficult to interpret and compare results from different studies, and standardisation of methodology and patient selection should be a priority in the future. Exchange of samples between laboratories could be a first step in investigating whether the discrepant results obtained in different studies are due to the different laboratory assays used, or reflect a true difference between the patient groups studied.

CD46

The human cell surface protein CD46 was recently identified as the cellular receptor for HHV-6 (38). Interestingly, this molecule also works as the receptor for the Edmonston strain of measles virus (80, 81), which has been suggested to be a possible MS-associated agent. CD46 is a regulator of complement activation, protecting autologous cells from complement-

405

TABLE 2. *Summary of results from different studies on detection of HHV-6 DNA and IgM to HHV-6 in MS patients and controls*

HHV-6 DNA						HHV-6 IgM		Reference
Cerebrospinal fluid		PBMC		Serum		Serum		
MS patients	Controls	MS patients	Controls	MS patients	Controls	MS patients	Controls	
		18/24 (75%)	12/20 (60%)	15/50 (30%)	0/47	14/22 (64%)f	3/35 (8.6%)	(67)
						6/14 (43%)h	7/40 (18%)	(104)
						15/21 (71%)	5/29 (17%)	(63)
		26/34 (76%)b	15/20 (75%)c	8/34 (23%)d	0/19	9/16 (56%)	4/162 (2.5%)	(70)
				2/32 (6.3%)	1/34 (2.9%)	1/55 (1.8%)		(105)
2/12 (17%)	0/4	3/56 (5.4%)	0/20					(106)
3/51 (5.9%)	1/17 (5.9%)			0/21	0/26			(73)
		7/34 (21%)e	0/20					(65)
3/21 (14%)	0/26			1/24 (4.2%)	0/30			(78)
				0/32	0/12			(107)
0/6	0/14					21/25 (80%)	5/33 (19%)	(74)
0/32	0/12	1/31 (3.2%)	1/24 (4.2%)					(66)
		2/14 (14%)	0/9					(64)
0/25	0/9					0/25	0/9	(108)
		8/20 (40%)	11/30 (37%)					(109)

a RRMS/CPMS, respectively.
b 87% HHV-6 variant A.
c 100% HHV-6 variant B.
d 80% HHV-6 variant A.
e 100% HHV-6 variant A.

mediated lysis, and is expressed n all human nucleated cells. There are different isoforms of CD46 and expression is dependent on the genetic background of the individual and on tissue-specific splicing (82, 83). It has been demonstrated that cells expressing CD46 mutants that lack a cytoplasmic part of the molecule are highly susceptible to measles virus infection and have a decreased ability to produce antiviral substances such as IFN-α/β and nitric oxide (84). This makes it tempting to speculate that individuals expressing a certain form of CD46 in the brain may respond inadequately to different infectious agent using this receptor, and that a receptor variant is a common finding in MS patients rather than one specific infectious agent. It has recently been demonstrated that clinical isolates of measles virus use SLAM (signalling lymphocytic activation molecule) rather than CD46 as a cellular receptor (85), but still the experimental evidence from the Edmonston strain can be used to speculate as to the mechanisms of virally induced disease.

Compared with previous evidence of a viral aetiology of MS, HHV-6 is of special interest since virally encoded proteins have indeed been found in oligodendrocytes in MS lesions. It is also known that HHV-6 is neuroinvasive and has the capacity to induce demyelination. Still the data on a possible link between HHV-6 and MS are conflicting, and most studies provide only indirect evidence by analysing antibody response or DNA detection for a ubiquitous virus. A way to prove more directly that a virus is important in MS pathogenesis could be to show a beneficial effect of antiviral treatment on the disease progress. One trial where MS patients were given antiviral drugs has been performed (86). This study was based on the hypothesis that herpes simplex virus is involved in MS, which was formulated upon the isolation of herpes simplex virus from CSF of a woman during her first attack of MS (87). A total of 60 MS patients with relapsing-remitting disease were followed for 2 years, 30 receiving 800 mg aciclovir daily and 30 receiving placebo in a double-blinded fashion. During this time the aciclovir group experienced 34% fewer exacerbations than the placebo group, but this was only a borderline significant difference (p = 0.08). Aciclovir is an antiviral compound with a documented effect on CNS infection with her-

pes simplex virus, but it has only a limited effect on β- and γ-herpesviruses, and the study is thus not very relevant for HHV-6. In order to target, for example, HHV-6 or EBV, it would be preferable to evaluate the two antiviral substances ganciclovir and foscarnet in a similar study.

MS is a heterogeneous disease, and the pathogenic mechanism is likely to be complex. Both autoimmune and virus-induced damage must be considered, and different viruses might even be associated with the disease in different individuals or different forms of the disease. Today it cannot be definitively concluded that HHV-6 is involved in MS pathogenesis.

REFERENCES

1. Sobel RA. The pathology of multiple sclerosis. Neurol Clin 1995;13:1-21.
2. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999; 12:295-302.
3. Esiri MM, Morris CS. Immunocytochemical study of macrophages and microglial cells and extracellular matrix components in human CNS disease. J Neurol Sci 1991;101:59-72.
4. Gale CR, Martyn CN. Migrant studies in multiple sclerosis. Prog Neurobiol 1995;47:425-48.
5. Kurtzke JF. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 1993;6:382-427.
6. Bobowick AR, Kurtzke JF, Brody JA, Hrubec Z, Gillespie M. Twin study of multiple sclerosis: an epidemiologic inquiry. Neurology 1978;28: 978-87.
7. Ebers GC, Bulman DE, Sadovnick AD, Paty FW, Warren S, Hader W, Murray TJ, Seland TP, Duquette P, Grey T, et al. A population-based study of multiple sclerosis in twins. N Engl J Med 1986;315:1638-42.
8. Kinnunen E, Juntunen J, Ketonen L, Koskimies S, Kouttinen YT, Salmi T, Koskenvuo M, Kaprio J. Genetic susceptibility to multiple sclerosis. A co-twin study of a nationwide series. Arch Neurol 1988;45:1108-11.
9. Sadovnick AD, Ebers GC, Dyment DA, Risch NJ. Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group. Lancet 1996;347:1728-30.
10. Olsson T, Zhi WW, Hojeberg B, Kostulas V, Jiang YP, Anderson G, Ekre HP, Link H. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J Clin Invest 1990;86:981-5.

11. Link H, Sun JB, Wang Z, Xu Z, Love A, Fredrikson S, Olsson T. Virus-reactive and autoreactive T cells are accumulated in cerebrospinal fluid in multiple sclerosis. J Neuroimmunol 1992;38:63–73.

12. Sun J, Link H, Olsson T, Xiao BG, Andersson G, Ekre HP, Linington C, Diener P. T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J Immunol 1991;146:1490–5.

13. Sun JB, Olsson T, Wang WZ, Xiao BG, Kostulas V, Fredrikson S, Ekre HP, Link H. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol 1991;21:1461–8.

14. Antel J, Brown M, Nicholas MK, Blain M, Noronha A, Reder A. Activated suppressor cell function in multiple sclerosis–clinical correlations. J Neuroimmunol 1988;17:323–30.

15. Rose LM, Ginsberg AH, Rothstein TL, Ledbetter JA, Clark EA. Selective loss of a subset of T helper cells in active multiple sclerosis. Proc Natl Acad Sci USA 1985;82:7389–93.

16. Svenningsson A, Andersen O, Hansson GK, Stemme S. Reduced frequency of memory CD8+ T lymphocytes in cerebrospinal fluid and blood of patients with multiple sclerosis. Autoimmunity 1995;21:231–9.

17. Granieri E, Casetta I. Common childhood and adolescent infections and multiple sclerosis. Neurology 1997;49:S42–54.

18. Andersen O, Lygner PE, Bergstrom T, Andersson M, Vahlne A. Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurol 1993;240:417–22.

19. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985;1:1313–5.

20. Karp CL, Wysocka M, Wahl LM, Ahearn JM, Cuomo PJ, Sherry B, Trinchieri G, Griffin DE. Mechanism of suppression of cell-mediated immunity by measles virus. Science 1996;273:228–31.

21. Adams J, Imagawa D. Measles antibodies in multiple sclerosis. Proc Soc Exp Biol Med 1962;111:562–6.

22. Ohara Y. Multiple sclerosis and measles virus. Jpn J Infect Dis. 1999;52:198–200.

23. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, de The G. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985;2:407–10.

24. Perron H, Geny C, Laurent A, Mouriquand C, Pellat J, Perret J, Seigneurin JM. Leptomeningeal cell line from multiple sclerosis with reverse transcriptase activity and viral particles. Res Virol 1989;140:551–61.

25. Perron H, Lalande B, Gratacap B, Laurent A,

26. Genoulaz O, Geny C, Mallaret M, Schuller E, Stoebner P, Seigneurin JM. Isolation of retrovirus from patients with multiple sclerosis. Lancet 1991;337:862–3.

26. Christensen T, Dissing Sorensen P, Riemann H, Hansen HJ, Moller-Larsen A. Expression of sequence variants of endogenous retrovirus RGH in particle form in multiple sclerosis. Lancet 1998;352:1033.

27. Olsson P, Ryberg B, Awad R, Ammoun S, Yin H, Hjalmarsson S, Blomberg J. Retroviral RNA related to ERV9/MSRV in a human serum: a new sequence variant. AIDS Res Hum Retroviruses 1999;15:591–3.

28. Haahr S, Sommerlund M, Christensen T, Jensen AW, Hansen HJ, Moller-Larsen A. A putative new retrovirus associated with multiple sclerosis and the possible involvement of Epstein-Barr virus in this disease. Ann N Y Acad Sci 1994;724:148–56.

29. Perron H, Suh M, Lalande B, Gratacap B, Laurent A, Stoebner P, Seigneurin JM. Herpes simplex virus ICP0 and ICP4 immediate early proteins strongly enhance expression of a retrovirus harboured by a leptomeningeal cell line from a patient with multiple sclerosis. J Gen Virol 1993;74:65–72.

30. Dahl H, Linde A, Sundqvistv VA, Wahren B. An enzyme-linked immunosorbent assay for IgG antibodies to human herpes virus 6. J Virol Methods 1990;29:313–23.

31. Hall CB, Long CE, Schnabel KC, Caserta MT, McIntyre KM, Costanzo MA, Knott A, Dewhurst S, Insel RA, Epstein LG. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med 1994;331:432–8.

32. Mukai T, Yamamoto T, Kondo T, Kondo K, Okuno T, Kosuge H, Yamanishi K. Molecular epidemiological studies of human herpesvirus 6 in families. J Med Virol 1994;42:224–7.

33. Yamanishi K, Okuno T, Shiraki K, Takahashi M, Kondo T, Asano Y, Kurata T. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 1988;1:1065–7.

34. Asada H, Klaus-Kovtun V, Golding H, Katz SI, Blauvelt A. Human herpesvirus 6 infects dendritic cells and suppresses human immunodeficiency virus type 1 replication in coinfected cultures. J Virol 1999;73:4019–28.

35. He J, MacCarthy M, Zhou Y, Chandran B, Wood C. Infection of primary human fetal astrocytes by human herpesvirus 6. J Virol 1996;70:1296–300.

36. Kondo K, Kondo T, Okuno T, Takahashi M, Yamanishi K. Latent human herpesvirus 6 infection of human monocytes/macrophages. J Gen Virol 1991;72:1401–8.

37. Saito Y, Sharer LR, Dewhurst S, Blumberg

BM, Hall CB, Epstein LG. Cellular localization of human herpesvirus-6 in the brains of children with AIDS encephalopathy. J Neurovirol 1995;1:30–9.

38. Santoro F, Kennedy PE, Locatelli G, Malnati MS, Berger EA, Lusso P. CD46 is a cellular receptor for human herpesvirus 6. Cell 1999;99: 817–27.

39. Inoue Y, Yasukawa M, Fujita S. Induction of T-cell apoptosis by human herpesvirus 6. J Virol 1997;71:3751–9.

40. Yasukawa M, Inoue Y, Ohminami H, Terada K, Fujita S. Apoptosis of CD4+ T lymphocytes in human herpesvirus-6 infection. J Gen Virol 1998;79:143–7.

41. Flamand L, Gosselin J, Stefanescu I, Ablashi D, Menezes J. Immunosuppressive effect of human herpesvirus 6 on T-cell functions: suppression of interleukin-2 synthesis and cell proliferation. Blood 1995;85:1263–71.

42. Horvat RT, Parmely MJ, Chandran B. Human herpesvirus 6 inhibits the proliferative responses of human peripheral blood mononuclear cells. J Infect Dis 1993;167:1274–80.

43. Li C, Goodrich JM, Yang X. Interferon-gamma (IFN-gamma) regulates production of IL-10 and IL-12 in human herpesvirus-6 (HHV-6)-infected monocyte/macrophage lineage. Clin Exp Immunol 1997;109:421–5.

44. Isegawa Y, Ping Z, Nakano K, Sugimoto N, Yamanishi K. Human herpesvirus 6 open reading frame U12 encodes a functional beta-chemokine receptor. J Virol 1998;72:6104–12.

45. Luster AD. Chemokines–chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436–45.

46. Caserta MT, Hall CB, Schnabel K, McIntyre K, Long C, Costanzo M, Dewhurst S, Insel R, Epstein LG. Neuroinvasion and persistence of human herpesvirus 6 in children. J Infect Dis 1994;170:1586–9.

47. Yamanishi K, Kondo K, Mukai T, Kondo T, Nagafuji H, Kato T, Okuno T, Kurata T. Human herpesvirus 6 (HHV-6) infection in the central nervous system. Acta Paed Jap 1992;34:337–43.

48. Barone SR, Kaplan MH, Krilov LR. Human herpesvirus-6 infection in children with first febrile seizures. J Pediatr 1995;127:95–7.

49. Hall CB, Caserta MT, Schnabel KC, Long C, Epstein LG, Insel RA, Dewhurst S. Persistence of human herpesvirus 6 according to site and variant: possible greater neurotropism of variant A. Clin Infect Dis 1998;26:132–7.

50. Asano Y, Yoshikawa T, Kajita Y, Ogura R, Suga S, Yazaki T, Nakashima T, Yamada A, Kurata T. Fatal encephalitis/encephalopathy in primary human herpesvirus-6 infection. Arch Dis Childhood 1992;67:1484–5.

51. Drobyski WR, Knox KK, Majewski DD, Carrigan DR. Brief report: fatal encephalitis due to variant B human herpesvirus-6 infection in a bone marrow-transplant recipient. N Engl J Med 1994;330:1356–60.

52. Huang LM, Lee CY, Lee Pi, Chen JM, Wang PJ. Meningitis caused by human herpesvirus-6. Arch Dis Childhood 1991;66:1443–4.

53. Ishiguro N, Yamada S, Takahashi T, Takahashi Y, Togashi T, Okuno T, Yamanishi K. Meningo-encephalitis associated with HHV-6 related exanthem subitum. Acta Paed Scand 1990;79: 987–9.

54. Knox KK, Harrington DP, Carrigan DR. Fulminant human herpesvirus six encephalitis in a human immunodeficiency virus-infected infant. J Med Virol 1995;45:288–92.

55. Sloots TP, Mackay IM, Carroll P. Meningoencephalitis in an adult with human herpesvirus-6 infection. Med J Aust 1993;159:838.

56. Yanagihara K, Tanaka-Taya K, Itagaki Y, Toribe Y, Arita K, Yamanishi K, Okada S. Human herpesvirus 6 meningoencephalitis with sequelae. Ped Infect Dis J 1995;14:240–2.

57. Yoshikawa T, Nakashima T, Suga S, Asano Y, Yazaki T, Kimura H, Morishima T, Kondo K, Yamanishi K. Human herpesvirus-6 DNA in cerebrospinal fluid of a child with exanthem subitum and meningoencephalitis. Pediatrics 1992;89:888–90.

58. McCullers JA, Lakeman FD, Whitley J. Human herpesvirus 6 is associated with focal encephalitis. Clin Infect Dis 1995;21:571–6.

59. Patnaik M, Peter JB. Intrathecal synthesis of antibodies to human herpesvirus 6 early antigen in patients with meningitis/encephalitis. Clin Infect Dis 1995;21:715–6.

60. Carrigan DR, Harrington D, Knox KK. Subacute leukoencephalitis caused by CNS infection with human herpesvirus-6 manifesting as acute multiple sclerosis. Neurology 1996;47: 145–8.

61. Novoa LJ, Nagra RM, Nakawatase T, Edwards-Lee T, Tourtellotte WW, Cornford ME. Fulminant demyelinating encephalomyelitis associated with productive HHV-6 infection in an immunocompetent adult. J Med Virol 1997;52: 301–8.

62. Challoner PB, Smith KT, Parker JD, MacLeod DL, Coulter SN, Rose TM, Schultz ER, Bennett JL, Garber RL, Chang M, et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci USA 1995;92:7440–4.

63. Ablashi DV, Lapps W, Kaplan M, Whitman JE, Richert JR, Pearson GR. Human Herpesvirus-6 (HHV-6) infection in multiple sclerosis: a preliminary report. Mult Scler 1998;4:490–6.

64. Sola P, Merelli E, Marasca R, Poggi M, Luppi

M. Montorsi M, Torelli G. Human herpesvirus 6 and multiple sclerosis: survey of anti-HHV-6 antibodies by immunofluorescence analysis and of viral sequences by polymerase chain reaction. J Neurol Neurosurg Psych 1993;56:917–9.

65. Wilborn F, Schmidt CA, Brinkmann V, Jendro-ska K, Oettle H, Siegert W. A potential role for human herpesvirus type 6 in nervous system disease. J Neuroimmunol 1994;49:213–4.

66. Friedman JE, Lyons MJ, Cu G, Ablashi DV, Whitman JE, Edgar M, Koskiniemi M, Vaheri A. Zabriskie JB. The association of the human herpesvirus-6 and MS. Mult Scler 1999;5:355–62.

67. Soldan SS, Berti R, Salem N, Secchiero P, Flam-and L, Calabresi PA, Brennan MB, Maloni HW, McFarland HF, Lin HC, Patnaik M, Jacobson S. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat Med 1997;3:1394–7.

68. Liedtke W, Malessa R, Faustmann PM, Eis-Hubinger AM. Human herpesvirus 6 poly-merase chain reaction findings in human im-munodeficiency virus associated neurological disease and multiple sclerosis. J Neurovirol 1995;1:253–8.

69. Enbom M, Martin C, Fredrikson S, Jägdahl L, Dahl H, Linde A. Intrathecal antibody produc-tion to lymphotropic herpesviruses in patients with multiple sclerosis. Neurol Infect Epidemiol 1997;XX:107–11.

70. Enbom M, Wang FZ, Fredrikson S, Martin C, Dahl H, Linde A. Similar humoral and cellular immunological reactivities to human herpesvi-rus 6 in patients with multiple sclerosis and con-trols. Clin Diagn Lab Immunol 1999;6:545–9.

71. Nielsen L, Larsen AM, Munk M, Vestergaard BF. Human herpesvirus-6 immunoglobulin G antibodies in patients with multiple sclerosis. Acta Neurol Scand 1997;169(suppl):76–8.

72. Martin C, Enbom M, Soderstrom M, Fredrik-son S, Dahl H, Lycke J, Bergstrom T, Linde A. Absence of seven human herpesviruses, includ-ing HHV-6, by polymerase chain reaction in CSF and blood from patients with multiple sclerosis and optic neuritis. Acta Neurol Scand 1997;95:280–3.

73. Merelli E, Bedin R, Sola P, Barozzi P, Mancardi GL, Ficarra G, Franchini G. Human herpes vi-rus 6 and human herpes virus 8 DNA se-quences in brains of multiple sclerosis patients, normal adults and children. J Neurol 1997;244:450–4.

74. Mirandola P, Stefan A, Brambilla E, Campad-elli-Fiume G, Grimaldi LME. Absence of hu-man herpesvirus 6 and 7 from spinal fluid and serum of multiple sclerosis patients. Neurology 1999;53:1367–8.

75. Mayne M, Krishnan J, Metz L, Nath A, Auty A, Sahai BM, Power C. Infrequent detection of human herpesvirus 6 DNA in peripheral blood mononuclear cells from multiple sclerosis pa-tients. Ann Neurol 1998;44:391–4.

76. Rotola A, Cassai E, Tola MR, Granieri E, Di Luca D. Human herpesvirus 6 is latent in pe-ripheral blood of patients with relapsing-remit-ting multiple sclerosis. J Neurol Neurosurg Psych 1999;67:529–31.

77. Knox KK, Carrigan DR. Active human her-pesvirus (HHV-6) infection of the central ner-vous system in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:69–73.

78. Kim J, Lee K, Park J, Kim M, Shin W. Detec-tion of human herpesvirus 6 variant A in pe-ripheral blood mononuclear cells from multiple sclerosis patients. Eur Neurol 2000;43:170–3

79. Soldan SS, Leist TP, Juhng KN, McFarland HF, Jacobson S. Increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients. Ann Neurol 2000;47:306–13.

80. Dörig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993;75:295–305.

81. Naniche D, Varior-Krishnan G, Cervoni F, Wild TF, Rossi B, Rabourdin-Combe C, Gerlier D. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 1993;67:6025–32.

82. Ballard L, Seya T, Teckman J, Lublin DM, At-kinson JP. A polymorphism of the complement regulatory protein MCP (membrane cofactor protein or gp45–70). J Immunol 1987;138:3850–5.

83. Russell SM, Sparrow RL, McKenzie IF, Purcell DF. Tissue-specific and allelic expression of the complement regulator CD46 is controlled by alternative splicing. Eur J Immunol 1992;22:1513–8.

84. Katayama Y, Hirano A, Wong TC. Human re-ceptor for measles virus (CD46) enhances nitric oxide production and restricts virus replication in mouse macrophages by modulating produc-tion of alpha/beta interferon. J Virol 2000;74:1252–7.

85. Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles vi-rus. Nature 2000;406:893–7.

86. Lycke J, Svennerholm B, Hjelmquist E, Frisen L, Badr G, Andersson M, Vahlne A, Andersson O. Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-con-trolled, double-blind study. J Neurol 1996;243:214–24.

87. Bergstrom T, Andersen O, Vahlne A. Isolation

of herpes simplex virus type 1 during first attack of multiple sclerosis. Ann Neurol 1989;26:283–5.

88. Margulis M, Soloviev V, Schubidze A. Aetiology and pathogenesis of acute sporadic disseminated encephalomyelitis and multiple sclerosis. J Neurol Neurosurg Psych 1946;9:62–74.

89. Gudnadottir M, Helgadottir H, Bjarnason O, Jonsdottir K. Virus isolated from the brain of a patient with multiple sclerosis. Exp Neurol 1964;9:85–95.

90. Palsson P, Pattison I, Field E. Transmission experiments with multiple sclerosis. In: Gajdusek C, Gibbs C, Alpers M, editors. Slow, latent and temperate virus infections. US Government Printing Office, Washington DC: 1965, 49–54.

91. Carp RI, Licursi PC, Merz PA, Merz GS. Decreased percentage of polymorphonuclear neutrophils in mouse peripheral blood after inoculation with material from multiple sclerosis patients. J Exp Med 1972;136:618–29.

92. ter Meulen V, Koprowski H, Iwasaki Y, Kackell YM, Muller D. Fusion of cultured multiple-sclerosis brain cells with indicator cells: presence of nucleocapsids and virions and isolation of parainfluenza-type virus. Lancet 1972;2:1–5.

93. Mitchell DN, Porterfield JS, Micheletti R, Lange LS, Goswami KK, Taylor P, Jacobs JP, Hockley DJ, Salsbury AJ. Isolation of an infectious agent from bone-marrows of patients with multiple sclerosis. Lancet 1978;2:387–91.

94. Wroblewska Z, Gilden D, Devlin M, Huang ES, Rorke LB, Hamada T, Furukawa T, Cummins L, Kalter S, Koprowski H. Cytomegalovirus isolation from a chimpanzee with acute demyelinating disease after inoculation of multiple sclerosis brain cells. Infect Immun 1979;25:1008–15.

95. Melnick JL, Seidel E, Inoue YK, Nishibe Y. Isolation of virus from the spinal fluid of three patients with multiple sclerosis and one with amyotrophic lateral sclerosis. Lancet 1982;1:830–3.

96. Vagabov RM, Skvortsova TM, Gofman Yu P, Barinsky IF. Isolation of the tick-borne encephalitis virus from a patient with multiple sclerosis. Acta Virol 1982;26:403.

97. Koprowski H, DeFreitas EC, Harper ME, Sandberg-Wollheim M, Sheremata WA, Robert-Guroff M, Saxinger CW, Feinberg MB, Wong-Staal F, Gallo RC. Multiple sclerosis and human T-cell lymphotropic retroviruses. Nature 1985;318:154–60.

98. Goswami KK, Randall RE, Lange LS, Russell WC. Antibodies against the paramyxovirus SV5 in the cerebrospinal fluids of some multiple sclerosis patients. Nature 1987;327:244–7.

99. Perron H, Garson JA, Bedin F, Beseme F, Paranhos-Baccala G, Komurian-Pradel F, Mallet F, Tuke PW, Voisset C, Blond JL, Lalande B, Seigneurin JM, Mandrand B. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The Collaborative Research Group on Multiple Sclerosis. Proc Natl Acad Sci USA 1997;94:7583–8.

100. Hodge MJ, Wolfson C. Canine distemper virus and multiple sclerosis. Neurology 1997;49:S62–9.

101. Munch M, Hvas J, Christensen T, Moller-Larsen A, Haahr S. The implications of Epstein-Barr virus in multiple sclerosis—a review. Acta Neurol Scand Suppl 1997;169:59–64.

102. Ross RT. The varicella-zoster virus and multiple sclerosis. J Clin Epidemiol 1998;51:533–5.

103. Sriram S, Stratton CW, Yao S, Tharp A, Ding L, Bannan JD, Mitchell WM. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol 1999;46:6–14.

104. Ablashi DV, Eastman HB, Owen CB, Roman MM, Friedman J, Zabriskie JB, Peterson DL, Pearson GR, Whitman JE. Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients. J Clin Virol 2000;16:179–91.

105. Akhyani N, Berti R, Brennan MB, Soldan SS, Eaton JM, McFarland HF, Jacobson S. Tissue distribution and variant characterization of human herpesvirus (HHV)-6: increased prevalence of HHV-6A in patients with multiple sclerosis. J Infect Dis 2000;182:1321–5.

106. Fillet AM, Lozeron P, Agut H, Lyon-Caen O, Liblau R. HHV-6 and multiple sclerosis. Nat Med 1998;4:537; discussion 538.

107. Goldberg SH, Albright AV, Lisak RP, Gonzalez-Scarano F. Polymerase chain reaction analysis of human herpesvirus-6 sequences in the sera and cerebrospinal fluid of patients with multiple sclerosis. J Neurovirol 1999;5:134–9.

108. Taus C, Pucci E, Cartechini E, Fie A, Giuliani G, Clementi M, Menzo S. Absence of HHV-6 and HHV-7 in cerebrospinal fluid in relapsing-remitting multiple sclerosis. Acta Neurol Scand 2000;101:224–8.

109. Rotola A, Caselli E, Cassai E, Tola MR, Granieri E, Luca DD. Novel human herpesviruses and multiple sclerosis. J Neurovirol 2000;6:S88–91.